The concept of engineering T cells to recognise tumour antigens emerged in the late 1980s, but decades of work were needed to make it clinically viable. Chimeric antigen receptor (CAR) T cells — autologous T cells genetically modified to express a synthetic receptor targeting a tumour surface antigen — showed dramatic complete remissions in early-phase studies of relapsed B-cell acute lymphoblastic leukaemia at the University of Pennsylvania and Memorial Sloan Kettering in 2013-2014.

Proof

Landmark RCTs and pivotal trials that established the evidence base

ELIANA (2018) was the pivotal registration trial for tisagenlecleucel in paediatric and young adult relapsed/refractory B-ALL, achieving an 81% overall response rate with 60% complete remission. ZUMA-1 (2017) established axicabtagene ciloleucel for refractory large B-cell lymphoma with 82% ORR and 54% complete response. These results — in patients who had exhausted all conventional options — led to the first FDA approvals of CAR-T therapies in 2017.

ZUMA-12017Landmark

ORR 82%; CR 54% in refractory large B-cell lymphoma

Molecular therapy : the journal of the American Society of Gene TherapySingle-arm phase 2N=111

ELIANA2018Landmark

ORR 81%; complete remission 60% in relapsed/refractory B-ALL

NEJMSingle-arm phase 2N=75

Extension

Follow-up studies, subgroup analyses, and real-world validation

CAR-T therapy rapidly expanded beyond B-ALL and DLBCL. KarMMa (2021) demonstrated idecabtagene vicleucel for relapsed/refractory multiple myeloma with 73% ORR. CARTITUDE-1 showed ciltacabtagene autoleucel achieving 97.9% ORR in heavily pretreated myeloma. The field also moved earlier in treatment lines — ZUMA-7 (2022) showed axi-cel superior to standard of care in second-line DLBCL.

KarMMa2021Landmark

ORR 73%; CR 33% at target dose in relapsed/refractory myeloma

NEJMSingle-arm phase 2N=128

CARTITUDE-12022Landmark

ORR 97.9%; sCR 82.5% in heavily pretreated myeloma

Journal of medical case reportsSingle-arm phase 1b/2N=97

Guidelines

Integration into clinical practice guidelines and recommendations

NCCN guidelines incorporated CAR-T as a standard option for relapsed/refractory B-ALL, DLBCL, follicular lymphoma, mantle cell lymphoma, and multiple myeloma. The American Society for Transplantation and Cellular Therapy (ASTCT) established consensus grading for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS), standardising toxicity management across centres.

NCCN B-Cell Lymphoma Guidelines

CAR-T recommended for relapsed/refractory DLBCL after first-line or second-line therapy

ASTCT Consensus Grading

Standardised CRS and ICANS grading and management algorithms

Now

Current standard of care and ongoing research directions

Six CAR-T products are FDA-approved across haematologic malignancies. Current research focuses on allogeneic (off-the-shelf) CAR-T to eliminate manufacturing delays, CAR-T for solid tumours, bispecific antibodies as potentially more accessible alternatives, and long-term safety surveillance including the rare risk of secondary T-cell malignancies.

Landmark Trials in This Story

ZUMA-12017Landmark

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

ORR 82%; CR 54% in refractory large B-cell lymphoma

Molecular therapy : the journal of the American Society of Gene TherapySingle-arm phase 2N=111

ELIANA2018Landmark

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

ORR 81%; complete remission 60% in relapsed/refractory B-ALL

NEJMSingle-arm phase 2N=75

KarMMa2021Landmark

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

ORR 73%; CR 33% at target dose in relapsed/refractory myeloma

NEJMSingle-arm phase 2N=128

CARTITUDE-12022Landmark

Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report

ORR 97.9%; sCR 82.5% in heavily pretreated myeloma

Journal of medical case reportsSingle-arm phase 1b/2N=97

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3M+ peer-reviewed articles.

Ask about CAR-T Cell Therapy Try AttendMe Free

Frequently Asked Questions

What is CAR-T cell therapy?+

CAR-T cell therapy involves collecting a patient's own T cells, genetically engineering them to express a chimeric antigen receptor that targets a specific tumour protein, expanding them in the laboratory, and infusing them back into the patient. The modified T cells then recognise and kill cancer cells bearing the target antigen.

What cancers can be treated with CAR-T?+

As of 2025, CAR-T is approved for B-cell acute lymphoblastic leukaemia (ELIANA), diffuse large B-cell lymphoma (ZUMA-1, TRANSCEND), follicular lymphoma, mantle cell lymphoma, and multiple myeloma (KarMMa, CARTITUDE-1). Research continues in solid tumours.

What are the main side effects of CAR-T therapy?+

The two major toxicities are cytokine release syndrome (CRS), characterised by fever, hypotension, and organ dysfunction from massive cytokine release, and immune effector cell-associated neurotoxicity syndrome (ICANS), involving confusion, seizures, or cerebral oedema. Both are graded and managed using standardised ASTCT protocols.